Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed CentralRead more →

Stage III Breast Cancer: Andrea's Survivor Story

Patient Info: Andrea, Female, Under 40 | Stage III

Completed chemotherapy, mastectomy/reconstruction, and radiation for Stage IIB-to-Stage III breast cancer diagnosed during pregnancy, and later described survivorship, parenting, fatigue, relationship strain, and recovery after treatment.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Margaret's Survivor Story

Patient Info: Margaret, Female | Stage II

Biomarkers: Onco-typing score 18; hormone-responsive tumor described; exact receptor status not reported

As of June 2026, Margaret’s story described completed surgery, chemotherapy, radiation, and later reconstruction for Stage II IDC/DCIS breast cancer, with survivorship focused on recovery, neuropathy, and integrative support rather than an explicit NED claim.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Lung cancer treated with tislelizumab: rare fluid buildup around the lung as a side effect

Patient Info: Anonymized, Male, 60s

After treatment of the bronchial-stump recurrence, the tumor remained stable. The delayed pleural effusion resolved within 10 days of methylprednisolone, and tumor stability continued for the next 15 months.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Stage II Ovarian Squamous Cell Carcinoma: Caitlin's Survivor Story

Patient Info: Caitlin Koehler, female, Under 40 | Stage II

Biomarkers: PD-L1: high expression

After surgery for recurrence, Caitlin remained on maintenance therapy and her follow-up scans showed no evidence of disease.

MD AndersonRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

Stage IV Ovarian Cancer First Found Through an Umbilical Metastasis

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: WT1-positive; CK7-positive; CA-125 321 U/mL at diagnosis

Metastatic Site: umbilicus

After 9 months of bevacizumab maintenance, her clinical and imaging findings remained stable.

PubMed CentralRead more →

Eight years cancer-free after treatment for a rare ovarian Brenner tumor

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: High Ki-67

At 8-year follow-up, surveillance showed no clinical or radiologic evidence of disease.

PubMed CentralRead more →

Durable response after multiple treatments for ovarian clear cell cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HRD-positive; BRCA-negative; ARID1A mutation; PD-L1 CPS 30

She achieved a complete response, completed maintenance immunotherapy in May 2024, and continued anlotinib with normal follow-up imaging and tumor markers.

PubMed CentralRead more →

Gastric cancer treatment during hemodialysis after liver recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver|peritoneum

The cancer progressed in the peritoneum despite treatment, and systemic therapy was stopped in August 2024 before transfer to hospice in October 2024.

PubMed CentralRead more →

Three separate primary cancers: lung squamous carcinoma, gastric adenocarcinoma, and hepatocellular carcinoma

Patient Info: Anonymized, Male, 60s

Biomarkers: Multiple primaries: lung squamous markers CK5/6 and P40; gastric cancer HER2 negative; liver cancer markers hepatocyte/GPC3/HSP70/CD34.

As of May 2026, all 3 primary cancers were controlled: lung cancer had no recurrence after surgery, gastric cancer remained in sustained remission on sintilimab maintenance, and hepatocellular carcinoma was controlled after ablation; ECOG performance status was 1.

PubMed CentralRead more →

Stage IV squamous NSCLC: durable pembrolizumab response followed by invasive aspergillosis, marrow failure, and death

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 20%

Metastatic Site: bilateral lungs

After durable partial response to pembrolizumab-based therapy, he developed severe pulmonary infection, invasive pulmonary aspergillosis, progressive AA-like bone marrow failure with severe cytopenias, declined further treatment, and died at home in early 2025.

PubMed CentralRead more →

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.

Stage II Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female | Stage II

Stage II breast cancer survivor after chemotherapy, with ongoing survivorship advice focused on hair loss, neuropathy, fertility preservation, nausea, fatigue, chemo brain, and support.

The Patient StoryRead more →

Stage III lung cancer treatment complicated by immune-related lung inflammation

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Mediastinal lymph nodes later enlarged despite additional systemic treatment, prompting radiation and further therapy.

PubMed CentralRead more →

Stage IV lung cancer response followed by immune-related lung inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Metastatic Site: pleura

After the lung inflammation improved, he did not resume tumor-directed chemotherapy, immunotherapy, or radiation and remained generally well.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Ovarian Cancer Remission Before Zolpidem Withdrawal Delirium

Patient Info: Anonymized, female

The ovarian cancer had not recurred for about 6 years, and she remained in remission.

PubMed CentralRead more →